| 000 | 05474nam a22004095i 4500 | ||
|---|---|---|---|
| 001 | 85381 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230207040508.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 160302s2016 gw | s |||| 0|eng d | ||
| 020 | _a9783319278834 | ||
| 040 | _aES-MaUEC | ||
| 050 | 4 |
_aRM315 _b2016 EB |
|
| 082 | 0 | 4 | _a615.78 |
| 245 | 1 | 0 |
_aApplied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents _cedited by Michael W Jann, Scott R Penzak, Lawrence J Cohen |
| 250 | _a1st ed. | ||
| 260 |
_aCham _bSpringer International Publishing _bImprint _bAdis _c2016 |
||
| 300 |
_a1 recurso en línea (XIV, 601 páginas) _b100 ilustraciones, 50 ilustraciones en color |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 505 | 0 | _aSection 1. General Pharmacokinetic and Pharmacodynamic Principles of Psychopharmacological Agents -- 1. Pharmacokinetic Properties -- 2. Pharmacodynamic Properties -- 3. PET Scan and Other Biomarkers -- 4. Population Pharmacokinetics -- 5. Drug Transporters (esp. Blood Brain Barrier) -- 6. Pharmacogenomics -- Section 2. Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Drug Classes -- 7. Antipsychotics � oral typical agents, oral atypical agents, and long-acting injectable (LAI) antipsychotics -- 8. Mood Stabilizers -- 9. Antidepressants � tricyclics, selective serotonergic reuptake inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase inhibitors, and other antidepressants -- 10. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 11. Opioid Analgesics -- 12. Stimulants and Other Non-Stimulants for ADHD -- 13. Cholinesterase Inhibitors and Other Antidementa Agents -- 14. Anti-Addiction Agents -- 15. Anesthetics -- Section 3. Clinically Significant Drug Interactions With Psychopharmacological Agents -- 16. Antipsychotics -- 17. Mood Stabilizers -- 18. Antidepressants -- 19. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 20. Opioid Analgesics -- 21. Stimulants and Other Non-Stimulants for ADHD -- 22. Cholinesterase Inhibitors and Other Antidementa Agents -- 23. Anti-Addiction Agents -- 24. Anesthetics. | |
| 520 | 3 | _aThis book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information forclinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous system (CNS) compartment are presented on an individual basis and then applied to target populations with specific disease states. Methods and characteristics that inform the transfer of these drugs from the laboratory bench to use in patient care are discussed, including imaging techniques, genetics and physiological barriers, such as the blood-brain barrier. The second section describes the characteristics of specific agents,nominally arranged intodifferent therapeutic categories and with reference crossover use in different disease states. The pharmacologic characteristics of different drug formulations are explored in the context of their ability to improve patient adherence. The third section focuses on drug-drug interactions.Psychotropic medications from different categories are frequently prescribed together,or alongside medications used to treat comorbid conditions, and the information provided is directly relevant to the clinic, as a result. The clinical application of pharmacokinetics and pharmacodynamics of CNS agents has made significant progress over the past 50 years and new information is reported by numerous publications in psychiatry, neurology, and pharmacology.Our understanding of the interrelationship between these medications, receptors, drug transporters, as well as techniques for measurement and monitoring their interactions,isfrequently updated. However, with information presented on a host of different platforms, and in different formats, obtaining the full picture can be difficult. This title aims to collate this information into a single source that can be easily interpreted and applied towards patient care by the clinical practitioner, and act as a reference for all others who have an interest in psychopharmacological agents. | |
| 710 | 2 |
_aSpringerLink (Online service) _0Local _9106996 |
|
| 942 |
_2lcc _cLE |
||
| 650 | 7 |
_aMedicina _0comprobar BNE19900959047 _2embne _9405021 |
|
| 650 | 7 |
_9139882 _aPsicofarmacología _0comprobar BNE19900978082 _2embne |
|
| 700 | 1 |
_aJann, Michael W. _eeditor literario _998299 _0Local |
|
| 700 | 1 |
_aPenzak, Scott R. _eeditor literario _998300 _0Local |
|
| 700 | 1 |
_aCohen, Lawrence J. _eeditor literario _931638 _0comprobar BNE20003868285 |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-27883-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 901 | _ai9783319278834 | ||
| 907 |
_a.b1294659x _b10-10-17 _c21-11-16 |
||
| 988 | _aSpringer_Medicine_2016 | ||
| 998 |
_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0 |
||
| 945 |
_aRM315 .A675 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11590336 _z06-04-17 |
||
| 999 |
_c85381 _d85381 _x1 |
||